346 related articles for article (PubMed ID: 34773048)
1. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1.
Rathnasinghe R; Salvatore M; Zheng H; Jangra S; Kehrer T; Mena I; Schotsaert M; Muster T; Palese P; García-Sastre A
Sci Rep; 2021 Nov; 11(1):22164. PubMed ID: 34773048
[TBL] [Abstract][Full Text] [Related]
2. Viral Subpopulation Screening Guides in Designing a High Interferon-Inducing Live Attenuated Influenza Vaccine by Targeting Rare Mutations in NS1 and PB2 Proteins.
Ghorbani A; Abundo MC; Ji H; Taylor KJM; Ngunjiri JM; Lee CW
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115873
[TBL] [Abstract][Full Text] [Related]
3. The Central Role of Non-Structural Protein 1 (NS1) in Influenza Biology and Infection.
Rosário-Ferreira N; Preto AJ; Melo R; Moreira IS; Brito RMM
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098424
[TBL] [Abstract][Full Text] [Related]
4. Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1.
Khalil AM; Nogales A; Martínez-Sobrido L; Mostafa A
Front Cell Infect Microbiol; 2024; 14():1357866. PubMed ID: 38375361
[TBL] [Abstract][Full Text] [Related]
5. Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine.
Matyushenko V; Isakova-Sivak I; Smolonogina T; Dubrovina I; Tretiak T; Rudenko L
PLoS One; 2017; 12(7):e0180497. PubMed ID: 28686625
[TBL] [Abstract][Full Text] [Related]
6. CpG dinucleotide enrichment in the influenza A virus genome as a live attenuated vaccine development strategy.
Sharp CP; Thompson BH; Nash TJ; Diebold O; Pinto RM; Thorley L; Lin YT; Sives S; Wise H; Clohisey Hendry S; Grey F; Vervelde L; Simmonds P; Digard P; Gaunt ER
PLoS Pathog; 2023 May; 19(5):e1011357. PubMed ID: 37146066
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of adenoviral vector expressing human interferon lambda-4 against influenza virus.
Kim DH; Kim JH; Lim KB; Lee JB; Park SY; Song CS; Lee SW; Lee DH; Choi IS
J Med Virol; 2024 Apr; 96(4):e29605. PubMed ID: 38634474
[TBL] [Abstract][Full Text] [Related]
8. Mathematical Modeling Suggests That Monocyte Activity May Drive Sex Disparities during Influenza Infection.
Liparulo TS; Shoemaker JE
Viruses; 2024 May; 16(6):. PubMed ID: 38932131
[TBL] [Abstract][Full Text] [Related]
9. Propylene glycol inactivates respiratory viruses and prevents airborne transmission.
Styles CT; Zhou J; Flight KE; Brown JC; Lewis C; Wang X; Vanden Oever M; Peacock TP; Wang Z; Millns R; O'Neill JS; Borodavka A; Grove J; Barclay WS; Tregoning JS; Edgar RS
EMBO Mol Med; 2023 Dec; 15(12):e17932. PubMed ID: 37970627
[TBL] [Abstract][Full Text] [Related]
10. A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model.
Strohmeier S; Amanat F; Zhu X; McMahon M; Deming ME; Pasetti MF; Neuzil KM; Wilson IA; Krammer F
mBio; 2021 Dec; 12(6):e0224121. PubMed ID: 34809451
[TBL] [Abstract][Full Text] [Related]
11. NS1 protein as a novel anti-influenza target: Map-and-mutate antiviral rationale reveals new putative druggable hot spots with an important role on viral replication.
Trigueiro-Louro J; Santos LA; Almeida F; Correia V; Brito RMM; Rebelo-de-Andrade H
Virology; 2022 Jan; 565():106-116. PubMed ID: 34773868
[TBL] [Abstract][Full Text] [Related]
12. The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection.
Møhlenberg M; Monrad I; Vibholm LK; Nielsen SSF; Frattari GS; Schleimann MH; Olesen R; Kjolby M; Gunst JD; Søgaard OS; O'Brien TR; Tolstrup M; Hartmann R
J Interferon Cytokine Res; 2021 Nov; 41(11):407-414. PubMed ID: 34788130
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
14. Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020-21 season.
Gasparini C; Acunzo M; Biuso A; Roncaglia S; Migliavacca F; Borriello CR; Bertolini C; Allen MR; Orenti A; Boracchi P; Zuccotti GV
Ital J Pediatr; 2021 Nov; 47(1):225. PubMed ID: 34774062
[TBL] [Abstract][Full Text] [Related]
15. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection.
Jiang Y; Duffy F; Hadlock J; Raappana A; Styrchak S; Beck I; Mast FD; Miller LR; Chour W; Houck J; Armistead B; Duvvuri VR; Yeung W; Haglund M; Wallner J; Wallick JA; Hardy S; Oldroyd A; Ko D; Gervassi A; Murray KM; Kaplan H; Aitchison JD; Heath JR; Sather DN; Goldman JD; Frenkel L; Harrington WE
PLoS One; 2021; 16(11):e0259902. PubMed ID: 34788328
[TBL] [Abstract][Full Text] [Related]
17. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.
McIlwain DR; Chen H; Rahil Z; Bidoki NH; Jiang S; Bjornson Z; Kolhatkar NS; Martinez CJ; Gaudillière B; Hedou J; Mukherjee N; Schürch CM; Trejo A; Affrime M; Bock B; Kim K; Liebowitz D; Aghaeepour N; Tucker SN; Nolan GP
Cell Host Microbe; 2021 Dec; 29(12):1828-1837.e5. PubMed ID: 34784508
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein as an effector molecule in Covid-19 pathogenesis.
Mosquera-Sulbaran JA; Pedreañez A; Carrero Y; Callejas D
Rev Med Virol; 2021 Nov; 31(6):e2221. PubMed ID: 34773448
[TBL] [Abstract][Full Text] [Related]
19. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Saito A; Irie T; Suzuki R; Maemura T; Nasser H; Uriu K; Kosugi Y; Shirakawa K; Sadamasu K; Kimura I; Ito J; Wu J; Iwatsuki-Horimoto K; Ito M; Yamayoshi S; Loeber S; Tsuda M; Wang L; Ozono S; Butlertanaka EP; Tanaka YL; Shimizu R; Shimizu K; Yoshimatsu K; Kawabata R; Sakaguchi T; Tokunaga K; Yoshida I; Asakura H; Nagashima M; Kazuma Y; Nomura R; Horisawa Y; Yoshimura K; Takaori-Kondo A; Imai M; ; Tanaka S; Nakagawa S; Ikeda T; Fukuhara T; Kawaoka Y; Sato K
Nature; 2022 Feb; 602(7896):300-306. PubMed ID: 34823256
[TBL] [Abstract][Full Text] [Related]
20. Frequency of respiratory pathogens other than SARS-CoV-2 detected during COVID-19 testing.
Boschiero MN; Duarte A; Palamim CVC; Alvarez AE; Mauch RM; Marson FAL
Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115576. PubMed ID: 34800846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
